Navigation Links
FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
Date:6/14/2011

SILVER SPRING, Md., June 14, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new genetic test that will help health care professionals determine if women with breast cancer are HER2-positive and, therefore, candidates for Herceptin (trastuzumab), a commonly used breast cancer treatment.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The test, called Inform Dual ISH, allows for measurement of the number of copies of the HER2 gene in tumor tissue. The HER2 gene is located on chromosome 17 in human cells. An excessive amount of the protein produced by the gene is found in some types of cancer cells, including breast cancer cells.

The Inform Dual ISH test allows lab personnel to count the number of copies of HER2 genes on chromosome 17 in a small sample of the breast tumor. The sample is stained with chemicals that cause copies of HER2 genes and chromosome 17 to change color. Copies of the HER2 gene appear black and copies of chromosome 17 appear red. These color changes can be seen under a standard microscope.

This feature allows lab personnel to see and count copies of chromosome 17 and HER2 genes on the same slide, similar to HER2 amplification measurements that have traditionally only been available using fluorescence microscopes. The Inform Dual ISH, however, allows lab staff to see the HER2 and chromosome 17 signals directly under a microscope, for longer periods of time.

"When used with other clinical information and laboratory tests, this test can provide health care professionals with additional insight on treatment decisions for patients with breast cancer," said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostic Device Evaluation and Safety in the FDA's Center for Devices and Radiological Health.

The FDA based its approval of the Inform Dual ISH on a U.S. study involving tumor
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... ANDOVER, Mass. , July 24, 2014   ... pulmonary function testing (PFT) employing precise ultrasound technology, announced ... as the instrument to measure Carbon Monoxide Diffusing Capacity ... Study, the most comprehensive study of Chronic Obstructive Pulmonary ... leading cause of death in the U.S. and affects ...
(Date:7/24/2014)... and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) announced today that the ... on Thursday, August 7, 2014, and that the Company ... 4:30 p.m. ET that afternoon. Management will provide an ... a general business update. To access ...
(Date:7/23/2014)... Australia , July 24, 2014 ... Melbourne , the agreement seeks to increase access ... At the AIDS 2014 conference in ... a new licensing agreement with Gilead Sciences for tenofovir alafenamide ... The licence will allow manufacturers in India ...
Breaking Medicine Technology:EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3
... Medical has been at the cutting edge of ... famous Resusci Anne in 1960. Fifty years on, ... launches its latest SimMan patient simulator, SimMan® Essential. ... (Photo: http://www.newscom.com/cgi-bin/prnh/20100830/NY56743 ) ...
... accelerating pace of scientific discovery in life sciences, coupled ... of genetic information, the field of personalized medicine has ... predictive and preventative care utilizing diagnostics that allow physicians ... therapeutic regimes are most effective, and determine long-term susceptibility ...
Cached Medicine Technology:Laerdal Introduces SimMan Essential 2Laerdal Introduces SimMan Essential 3Personalized Medicine: Conference Provides Update on Progress and Prospects 2
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 On October ... ones will descend upon the Embassy Suites LAX North for ... hosted by DiabetesSisters and the first time it has convened ... time for the organization to open the entire event to ... the only conference of its kind worldwide for women with ...
(Date:7/24/2014)... July 24, 2014 (HealthDay News) -- A new formulation ... from snorting or injecting the drug has been approved ... Targiniq ER and made by Purdue Pharma, the pill ... a drug that blocks the euphoric effects of oxycodone. ... crushed, snorted, dissolved or injected, according to the FDA. ...
(Date:7/24/2014)... 24, 2014 Skirt Sports, the innovative women’s ... of the running skirt. Born from an idea by professional ... an Ironman race in 2004, this one innovative piece of ... prize money from her victory in Wisconsin to incorporate Skirt ... specific athletic skirts. , “When I drew the first sketch ...
(Date:7/24/2014)... July 24, 2014 The North American Omega ... omega 3 & structured lipids market in North America with ... is estimated to grow from around $762.4 million in 2012 ... from 2013 to 2018. , Browse through the TOC of ... to get an idea of the in-depth analysis provided. This ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... to announce a new distribution agreement with game ... collaboration between the two groups to offer ... clinicians using biofeedback and neurofeedback in European and ... “video game” developed expressly to be used as ...
Breaking Medicine News(10 mins):Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 3Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 3Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $1,117 million in 2018 - New Report by MicroMarket Monitor 5Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 2Health News:Biofeedback Federation of Europe Enters Distribution Agreement with Zukor Interactive 3
... are seeing the first signs of a reverse brain ... grow over time. The emergence of modern,corporate and investorowned ... NRI doctors back to home turf. ,And unlike other ... the main draw, doctors are actually taking pay cuts ...
... together will build the worlds first "all digital ... by the out patient surgical rehabilitation chain. The ... screens connected to the Internet, electronic medical records ... permitting doctors and other caregivers to access patients' ...
... in the United States of America, says that children suffer ... an unhappy marriage and avoid a divorce for the sake ... only do more damage to the kids, the authors of ... of Pennsylvania State University in University Park conducted the exhaustive ...
... giants has just begun. After waging wars over many drug ... treatment. The ball was set in motion by the dramatic ... AIDS treatment would cost less than a U.S. dollar a ... announced plans of its own production of anti retroviral drugs ...
... humour. It stirred up a controversy. Now it is being ... officially announced that the advertisement in question might not be ... they did not enjoy the advertisement poking fun at organ ... a carousel horse. A team of medics approaches him and ...
... the tedious process of finding survivors of the Gujarat quake, from ... more survivors. They are now concentrating in clearing the rubble and ... far. A miracle baby was saved after nearly 90 hours under ... holding on to the dead body of its mother. The baby ...
Cached Medicine News:Health News:Lure of the home turf brings back NRI doctors 2
Raysoft Foldable Intraocular Lens....
XL OCTO Hydrophilic Acrylic Lens....
... The Collamer™ lens, model CQ2003V, combines the ... design. This lens contains a Collamer optic ... no angulation. These loops offer flexibility comparable ... tensile strength, and superior "shape memory". The ...
Biocryl™ Acrylic Foldable Lens....
Medicine Products: